While no independent research has been conducted on the Whole30 diet specifically, diets like this one that eliminate entire food groups are bound to make you drop weight, experts say. That was the case for 96 percent of 1,600 Whole30 participants, according to a survey by the company. Most Whole30 dieters lost between 6 and 15 pounds, the survey found. But experts worry that restrictive diets with no room for error can set followers up for failure and prompt them to put the pounds back on – and then some – once the diet is over.
Glassman is proud of his role in all this, but the system puts him and CrossFit at a very real risk. As the world of CrossFit grows, as more businesses enter and profit, and his share of it becomes smaller, CrossFit's greatest success--gaining mainstream acceptance as exercise and a sport--could turn it generic, like baseball or skiing. "One of our greatest fears is becoming escalator," says Dale Saran, CrossFit's general counsel, referring to what was once a trademarked name brand of Otis Elevator. So, although Glassman keeps the CrossFit business model radically loose and open, he protects the brand name with an iron fist.
The Great Cholesterol Con: The Truth About What Really Causes Heart Disease and How to Avoid It by Dr. Malcolm Kendrick reveals that high cholesterol levels do not cause heart disease; that high-fat diets–saturated or otherwise–do not affect blood cholesterol levels; and that for most men and all women the benefits offered by statins are negligible at best. Other data is also provided that shows that statins have many more side affects than is often acknowledged.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”